



## Call for Proposals 2023

### "Natural History Studies addressing unmet needs in Rare Diseases"

## Guidelines for Applicants

**Submission deadline for pre-proposals: February 15th, 2023, at 2 PM (CET)**

**For further information,**

An **information webinar** will be held on **December 15<sup>th</sup>**, 14:30 – 16:00 (CET). You will need to register to participate in the webinar here:

<https://forms.office.com/r/CLYFTuzRyw>

**Visit us on the web:**

<http://www.ejprarediseases.org/>

### Contact Joint Call Secretariat

French National Agency for Research (ANR, France)

Dr Florence GUILLOT  
Dr Camille de Almeida  
Dr Ingrid Pfeifer  
[EJPRDcall@anr.fr](mailto:EJPRDcall@anr.fr)

## Table of Contents

1. Application Process .....	3
1.1 Registration .....	3
1.2 Pre- and Full Proposals .....	3
1.3 Rebuttal stage .....	3
2. Advice for preparing your proposal.....	3
3. Project description.....	4
4. Early Career Researchers (ECRs) .....	7
4.1 Definition .....	7
4.2 Eligibility of ECRs .....	7
5. Financial and Legal Issues .....	8
5.1 Funding model and Call governance.....	8
5.2 Widening for the inclusion of under-represented or under-subscribed countries	8
5.2.1 Definition of widening .....	8
5.2.2 Process .....	9
5.3 EJP RD Clinical Support Services.....	9
5.4 Funding contracts.....	10
5.5 Project start and consortium agreement.....	10
5.6 Ownership of intellectual property rights .....	11
5.7 IRDiRC policies and guidelines.....	11
5.8 European and International standards .....	11
5.9 Publication of Results.....	12
6. General Data Protection Regulation.....	13
ANNEX 1: Country and Region-Specific Guidelines.....	14
BELGIUM, FRENCH SPEAKING COMMUNITY, F.R.S.-FNRS .....	14
CANADA, CIHR-IG .....	16
FRANCE, ANR.....	18
GERMANY, BMBF/PT-DLR .....	20
GERMANY, DFG.....	22
HUNGARY, NKFIH.....	24
IRELAND, HRB .....	26
ISRAEL, CSO-MOH.....	28
ITALY, IT-MoH.....	30
ITALY, LOMBARDY, FRRB.....	33
ITALY, TUSCANY, RT/TuscReg .....	36
ITALY, FTELE .....	39
LITHUANIA, LMT .....	41
LUXEMBURG, FNR .....	43
POLAND, NCBR .....	45
SLOVAKIA, SAS.....	47
SPAIN, ISCIII .....	49
SWEDEN, SRC .....	54
SWEDEN, VINNOVA .....	56
SWITZERLAND, SNSF.....	58
TÜRKIYE, TUBITAK .....	60

## 1. Application Process

### 1.1 Registration

Research consortia who intend to submit a transnational project proposal should register via the electronic proposal system: <https://ptoutline.eu/app/ejprd23>. Please fill in the data sheet in the system. The same data sheet can be used for the submission of pre-proposals and full proposals (if invited).

### 1.2 Pre- and Full Proposals

There will be a **two-stage submission procedure for joint applications**: a pre- and full proposal stage. In both cases, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal and must be submitted by the coordinator only to the JCS via the electronic submission system: <https://ptoutline.eu/app/ejprd23>. Proposals must be prepared using the templates provided on the EJP RD web page ([www.ejprarediseases.org](http://www.ejprarediseases.org)). Proposals not conforming to template instructions (including length and format) will be rejected.

You will not need to submit a paper version of your proposal; however, both the **electronic pre-proposals and full proposals need to be signed** (electronic signature or a scanned copy of the signature page will be accepted).

**Joint pre-proposals (in English) must be received by the JCS in an electronic version no later than February 15<sup>th</sup>, 2023 at 2:00 p.m. Central European Time (CET).**

**Full proposals (in English) must be received by the JCS in an electronic version no later than June 14<sup>th</sup>, 2023 at 2:00 p.m. Central European Summer Time (CEST).**

### 1.3 Rebuttal stage

Please note that project coordinators will be provided with the opportunity to study the assessments of external reviewers and comment on their evaluations of full proposals (for details see section 7.3 in the “Call text” document).

## 2. Advice for preparing your proposal

Carefully read the “Call Text” and this “Guidelines for Applicants” document, including the call aim, evaluation criteria and national eligibility criteria and requirements.

Proposals not conforming to the following may be rejected without review:

- Make sure that your proposal falls into the scope of the call (Section 4 of the call text);
- Make sure that your proposal fulfils the eligibility criteria of the call (Section 5 of the call text);
- Make sure that all consortium members have understood the national eligibility criteria and requirements (Annex 1) and that they fulfil these criteria;

- Make sure that all consortium members contacted their national representative and enquired about their eligibility with their respective funding organizations in advance of submitting an application (see Annex 1);
- Prepare your proposal in advance and enter the requested information on the submission site as soon as possible to avoid possible overloading on the submission deadlines;
- Use the proposal templates provided on the EJP RD website ([www.ejprarediseases.org](http://www.ejprarediseases.org));
- Respect the length limitations of each section in the proposals.

### 3. Project description

*Applicants will describe and justify the following elements:*

*The elements marked with a “\*” will have to be developed only for full proposals*

#### **Background, present state of the art in the research field**

- Need for research rationale: description of the unmet need that is addressed by the proposed work, rationale of the rare diseases chosen
- Present state of the art, recent insight from literature
- Preliminary results obtained by the consortium members

#### **Objectives and hypothesis**

- Main and secondary hypothesis

#### **Soundness and pertinence**

- Innovative aspects, originality, novelty
- Social care and public health interest
- Applicants should include information about other ongoing development work and explain why their approach should be supported\*.

#### **Workplan & methodology** (*highlighting feasibility*)

- Research strategy
- Methodologies justification and presentation
- Enrollment: study location(s), inclusion/exclusion criteria, total number of corresponding patients followed by partners and collaborators of the project.
- Number of participants calculation (if applicable): description, justification, expected response rate.
- Statistical power (if applicable): appropriate statistical methods description, name and affiliation of the responsible biostatistics' expert.
- \*Quality monitoring (only for full proposal): risk management, contingency plans (identification of possible bottlenecks and go/no go steps).

#### **Impact**

- Results: description of expected results and their implementation
- Impact: description of the potential impact of the expected results on the addressed unmet need
- Benefits: description of individual and collective benefits that could be expected

#### **\*Valorization, translation in practice**

- Effective measures to exploit and disseminate the project results, to communicate the project, and to manage research data
  - o Present / future position regarding intellectual property rights, both within and outside the consortium
  - o Scientific communication (articles, presentations...): description of plan, tools and responsibilities for communication towards clinical community
  - o PAO/Public communication: description of plan, tools and responsibilities for communication towards PAOs, patients, any concerned people
- Innovative potential: relevant application for rare diseases care
- Translatability: opportunities to exploit the methodology and/or expected results for other rare and non-rare diseases
- Sustainability: description of plan for sustainability of infrastructures or resources initiated by the project, follow-on funding and/or draft study plans past the grant end, articulation with other existing research infrastructures\*\*.

#### **\*Ethical and legal issues, data management**

- Ethical and legal issues management plan description, including:
  - o the recruitment of participants (e.g. direct/indirect incentives for participation, the risks and benefits for the participants etc.)
  - o the material collection (e.g. sensitive or personal data etc.)
  - o ensuring the wellbeing of the children involved
  - o ensuring consentSee [H2020 Guidance "How to complete your ethics self-assessment"](#)
- GDPR management: plan description, name and affiliation of the Data Protection Officer (DPO).
- Data management strategy: plan description to make research data that are generated in the project findable, accessible, interoperable and re-usable for humans and machines (FAIR), i.e. enabling reuse by enhancing machines to automatically find and use the data on behalf of users outside of the project consortium and beyond the lifetime of the project. For the proposal it is minimally required that one or more individuals in the consortium are designated to spend part of their time on executing a FAIR implementation plan (the 'local' data steward role). The amount of time is proportionate to the complexity of the data that are generated (e.g. the number of columns in tabular output). An acceptable strategy is to plan for developing and executing the plan in collaboration with a FAIR expert group. In that case, it is not required to include a detailed FAIR implementation plan in the proposal. The expertise of the FAIR group should include experience in FAIR data stewardship and understanding of the technical specifications of the EJP RD virtual platform. It is possible to indicate that a FAIR expert partner will be found through the EJP RD helpdesk.

#### **Work packages, timeline and budget**

- Description of the aims/work packages: synopsis and timeframe, including project coordination and management as well as \*innovation management activities
- \* Justification of requested budget: rational distribution of resources in relation to project's activities, partners responsibilities and time frame; please also specify co-funding from other sources necessary for the project if applicable

- Diagram which compiles the work plan, timeline, sequencing of work packages, contribution of the partners to each work package and their interactions (Gantt chart, Pert or similar)

### Responsibilities and workloads

- For each research partner: letter of intent (for the full proposal); competence and experience in the field(s) of the proposal (previous work in the field, specific expertise); responsibilities in each work package; \*ongoing or submitted research grants.
- For PAO/patient representative: role and contribution, access to and engagement of patients, responsibilities in each work package.
- Added values: complementarity of the participants within the consortium, benefit of transnational collaboration
- \*Management plan: operating and coordination methods

### PAOs engagement/involvement

- The Research Proposal must clearly indicate how the PAO/patient representative will be actively and meaningfully engaged in the project activities (For more details, see: [Patients in research – EJP RD – European Joint Programme on Rare Diseases](#))

*\*Those elements will have to be developed only for full proposals*

**\*\*The use of existing European health research infrastructures and/or IRDiRC recognized resources is strongly encouraged when appropriate:** e.g. research infrastructures established as a European Research Infrastructure Consortium (ERIC) or identified on the roadmap of the European Strategy Forum on Research Infrastructures (ESFRI). Projects are invited to identify the existing European research data infrastructures that may be used and how these may be mobilized, in particular for long-term data curation and preservation, when needed (in accordance with EU and [IRDiRC recommendations](#)). The following ESFRI European Research Infrastructures and European/international projects or their results may be of use to consortia:

- [BBMRI](#) Biobanking and Biomolecular Resources Research Infrastructure
- [ELIXIR](#) The European Life Sciences Infrastructure for Biological Information, the ELIXIR Research Data Management Kit ([RDMkit](#)) and about the [rare disease data](#)
- [INFRAFRONTIER](#) European Infrastructure for Phenotyping, Archiving and Distribution of Mouse Models
- [INSTRUCT](#) Integrated Structural Biology Infrastructure for Europe
- [EU-OPENSREEN](#) European high-capacity screening network
- [EATRIS](#) European Infrastructure for Translational Medicine
- [Rd-Connect](#) An integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research
- [IRDiRC recognized resources](#)
- [Matchmaker Exchange](#) Federated platform to facilitate the matching of cases with similar phenotypic and genotypic profiles
- [Horizon 2020 FAIR Data Management Plan](#) Annex 1
- [Orphanet Rare Disease Ontology](#)
- [Human Phenotype Ontology](#)
- [Recommendations for Improving the Quality of Rare Disease Registries](#)
- [EJPRD IMT – Innovation Management Toolbox](#) Reference library of resources in rare disease translational medicine
- The [Virtual Platform](#) (VP) of the European Joint Programme Rare Diseases – (EJP RD), a platform that gives access to federated data and samples in FAIR resources that

have implemented the specifications of the EJP RD VP. Data generating projects are expected to contribute to the VP by implementing FAIR principles.

- [PROMs Repository | ERICA](#)
- [Rare Diseases Clinical Trials Toolbox – EJP RD](#) (see sections: Data Management Plan and Data Management)

\*\*\* The [EJP RD's Resource Finder](#) provides scientific partners with a vast number of existing research data and services grouped into categories and represented as 11 `nodes` in the mindmap.

## 4. Early Career Researchers (ECRs)

### 4.1 Definition

ECRs are defined as per the regulations of the European Research Council criteria for starting grants. In short, the researcher must have been awarded their first doctoral degree (**PhD**) **two to seven years prior to the pre-proposal submission deadline**. Extensions to this period are allowed (with documentation) in the case of reasonably justified career breaks: absence for maternal, paternal or long-term sick leave, and compulsory military service.

For medical doctors (or applicants holding a degree in medicine), an MD is not by itself considered equivalent to a PhD award. To be considered an ECR, these applicants must provide the certificates of both a medical doctor degree and a PhD, or proof of an appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment). MD applicants that do not hold a PhD must have been awarded their **MD four to nine years prior to the pre-proposal submission deadline**. For medical doctors who have been awarded both an MD and a PhD, the date of the earliest degree that makes the applicant eligible will be used to calculate eligibility. Extensions to this period will be given (with documentation) for clinical training periods up to a maximum of four years.

### 4.2 Eligibility of ECRs

The following dates must be provided by Early Career Researchers so that their eligibility can be evaluated according to their respective regional/national regulations. **This information must be present in the CV in the pre- and full proposal forms.**

#### **Medical doctors with PhD**

Medical Studies: *indicate dates (start and end) of your studies (year and month)*

End of studies: *indicate date of your medical certificate*

PhD Time: *indicate dates (start and end) of your PhD time (year and month)*

PhD: *indicate date of your PhD certificate*

Appointment: *indicate dates (start and end) of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment), only if applicable*

#### **Medical doctors without PhD**

Medical Studies: *indicate dates (start and end) of your studies (year and month)*

End of studies: *indicate date of your certificate*

Appointment: *indicate dates of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment)*

#### **Other Early Career Scientists with PhD**

Studies: *indicate dates (start and end) of your studies (year and month)*

End of studies: *indicate date of your certificate*

PhD Time: *indicate dates (start and end) of your PhD time (year and month)*

PhD: *indicate date of your PhD certificate*

#### **Other Early Career Scientists without PhD**

Studies: *indicate dates (start and end) of your studies (year and month)*

End of studies: *indicate date of your certificate*

Appointment: *indicate dates of the appointment that requires doctoral equivalency (e.g. post-doctoral fellowship or professorship appointment)*

#### **Reasons for Extensions, if applicable**

Clinical Training: *indicate dates (start and end) of clinical training (year and month);*

Parental leave: Women: *number of children (1.5 years are given per child; in case of longer maternal leave, please indicate the exact dates); Men: indicate exact dates of paternal leave (per child)*

Career Break: *indicate dates (year and month) of other career breaks: long-term sick leave, compulsory military service, career's leave*

## **5. Financial and Legal Issues**

### **5.1 Funding model and Call governance**

The EJP RD JTC 2023 Funding Partners have agreed to launch a joint call using the **“virtual common pot” funding mode**. This means that national/regional funding will be made available through national/regional funding organizations according to national/regional funding regulations.

**ANR (France) is acting as Joint Call Secretariat (JCS)** to assist the Call Steering Committee (CSC), and the national/regional funding bodies during the implementation of the call.

The JCS will be responsible for the administrative management of the call. It will be the primary point of contact referring to the call procedures between the research consortia, the funding organizations (CSC), and the peer reviewers. The project **coordinator will be the point of contact for the JCS** during the application procedure and is responsible for forwarding this information to other partners.

CSO-MOH (Israel) and FNRS (Belgium) will be responsible for the follow-up phase until the funded research projects have ended.

### **5.2 Widening for the inclusion of under-represented or under-subscribed countries**

#### **5.2.1 Definition of widening**

For proposals invited to the full proposal stage, there will be a widening step to provide the **opportunity to add partners** to the consortium (up to a maximum total of 8, see

section 5.4 *Consortium Makeup* of the Call Text). This step will allow for the addition of partners from participating countries that are usually underrepresented in the call, as well as those undersubscribed (countries without any selected applicants for the 2<sup>nd</sup> stage). This inclusion will not be considered as a fundamental change between pre- and full proposal. **Inclusion of new research partners is not mandatory. The new partners included should bring an added value and expertise to the projects.**

### 5.2.2 Process

A list of countries eligible for this widening procedure will be published on the EJP RD website after completion of the 1<sup>st</sup> stage of evaluation and sent to the coordinators that are invited to write a full proposal.

The relevant national funding agencies may produce a list of research partners that could provide additional expertise to projects. **For this, the title, pre-proposal abstract, and composition of the consortium will be shared with potentially interested research teams.** The JCS will then provide this list to the coordinators of projects invited to the full proposal stage and give them the option of adding them to the existing consortium.

The coordinator/partners of projects invited to the 2<sup>nd</sup> stage of evaluation can also inquire themselves about suitable partners from among listed countries. The new prospective partner must then contact their national funding agency to confirm their eligibility. The new prospective partner willing to join more than one research consortium should make sure first that it will fulfil its national/regional rules. Secondly, the new prospective partner must ensure to be able to complete its tasks in the different research consortia that she/he intends to join. On the other hand, the funding organisation participating in the widening process must ensure its oversubscription rate remain within the average oversubscription rate of all the other funding organisations unless the funding commitment can be raised.

In all cases, the final decision on whether to take a new research team on board will be taken by the project consortium. The rules concerning the maximum number of partners in a consortium and the maximum of two research teams per country must still be respected. Furthermore, the new research team must be eligible for the national funding agency. For this purpose, national funding agencies from underrepresented or undersubscribed countries may indicate that only national research teams that were already involved in pre-proposals (and thus are eligible) are allowed to make use of this widening step.

## 5.3 EJP RD Clinical Support Services

Applicants that are invited to submit a second stage proposal are strongly encouraged to make use of the EJP Rare Diseases [Clinical Support Services](#). This completely free service offered by EJP RD and coordinated by [ECRIN](#) will provide independent feedback and advice to applicants in the scientific design and operational planning of their NHS. This will help to ensure robust and reliable study results so that the project – if successful – has the best chances of advancing towards implementing the results for patient care. These areas include:

- Methodology tailored to small populations
- Innovative statistical design
- Country selection/Site mapping
- Regulatory and Ethical requirements
- Cost evaluation.

EMA does not have specific guidelines for NHS, the FDA has produced a [Draft Guide | FDA](#) which is relevant for this call, apart from the parts on data collection and Human Subject protection where EU legislation should apply.

NHS can be based on data collected in registries where guidelines can be found at the following links: [Guideline on registry-based studies](#), [The voice of rare disease patients](#).

Other EMA Guidelines can be suitable for this call topic:

- [Complex Clinical Trials](#);
- [Paediatrics investigations](#);
- [Regulatory Perspective on Real World Evidence in scientific advice](#).

Videos on NHS were also published on youtube:

- [Natural History Studies for Rare Diseases - YouTube](#)
- [Natural History vs. Registry Studies in Rare Disease: Which, When, and How? - YouTube](#)

## 5.4 Funding contracts

Each project includes several partners (including a project coordinator) as beneficiaries. **Each partner will have a separate funding contract/letter of grant with their respective national/regional funding organizations, and according to their regulations.**

Changes to the composition of research consortia or budget cannot occur within the contract/letter of grant without thorough justification. Minor changes will be handled by the relevant national/regional funding agency. In the case of major changes, an independent expert may be consulted to help with the final decision of the funding organizations. **Research partners must inform the JCS and the respective funding bodies of any event that might affect the implementation of the project.**

## 5.5 Project start and consortium agreement

Consortium members of projects selected for funding **must fix a common project start date**, which will be the reference date for yearly and final reports and extensions. This common project start date must appear in the **Consortium Agreement (CA)**.

The project consortium partners must sign a CA for cooperation. For reference see the [DESCA 2020 Model Consortium Agreement](#). It is recommended that the CA be signed by all relevant parties before the official project start date. Please note that national/regional regulations may apply concerning the requirement for a CA (please contact your national/regional contact point or check Annex 1). This consortium agreement must be made available upon request or per national/regional to the relevant EJP RD JTC 2023 funding organizations.

The purpose of the CA shall be:

- to underpin the collaboration and provide research partners with mutual assurance on project management structures and procedures, and their rights and obligations towards one another
- to assure the CSC that the research consortium has a satisfactory decision-making capability and is able to work together in a synergistic manner

The following subjects should be addressed by the CA (at minimum):

- purpose of and definitions used in the CA
- names of organisations involved
- common start date of the research project
- organisation and management of the project
- role and responsibilities of the research consortium coordinator and the research partners: person in charge, their obligations and key tasks, conditions for their change
- deliverables (transnational reports and, if relevant, requirements for national reports where coordination is required)
- resources and funding
- confidentiality and publishing
- intellectual property rights (how this issue will be handled between research partners)
- decision making within the consortium
- handling of internal disputes
- the liabilities of the research partners towards one another (including the handling of default of contract)
- exploitation of results
- risk management and management of contingency issues
- data reuse: access to project-generated data for reuse outside of the consortium and beyond the runtime of the project (aka FAIR data publishing).

## 5.6 Ownership of intellectual property rights

Results and Intellectual Property Rights (IPR) resulting from projects funded through the EJP RD JTC 2023 will be owned by the beneficiaries' organizations according to national/regional rules on IPR. In the case of joint development of intellectual property, consortium partners will resolve this issue internally using their consortium agreement and relevant legal guidelines and taking into account their relative contributions.

**The results of the research project and IPR created should be actively exploited and made available for use**, whether for commercial gain or not, in order for public benefit to be obtained from the knowledge created.

**The funding organizations shall have the right to use documents, information and results submitted** by the research partners and/or to use the information and results for their own purposes, provided that the owner's rights are kept and taking care to specify their origin.

## 5.7 IRDiRC policies and guidelines

The project partners are expected to follow [IRDiRC policies and guidelines](#).

## 5.8 European and International standards

The submitted proposals must respect relevant European and international standards including:

- [H2020 ethics manual](#) for research projects,
- [The Declaration of Helsinki](#) Ethical Principles for Medical Research Involving Human Subjects,

- The General Data Protection Regulation (GDPR): the European Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data:
- <https://publications.europa.eu/en/publication-detail/-/publication/3e485e15-11bd-11e6-ba9a-01aa75ed71a1/language-en>; The EC Directive 2010/63/EU on the protection of animals used for scientific purposes,
- [European Research Council Guidelines on Implementation of Open Access to Scientific Publications and Research Data](#);
- To make research data findable, accessible, interoperable and re-usable (FAIR), a [data management](#) strategy is mandatory in the full proposal. [Example questions for a data management strategy](#);
- General ethical and legal requirements: Ethics is an integral part of research. Ethics should be embedded in the research and considered from the outset, and although legal and regulatory considerations may vary across different countries, EJPRD will only fund proposals which comply with national and international ethical standards, rules and legislations;
- International Ethical Guidelines for Biomedical Research Involving Human Subjects CIOMS-WHO (2016);
- Oviedo Convention and its Additional Protocol on human rights and biomedicine, concerning biomedical research (2005);
- COUNCIL OF EUROPE COMMITTEE OF MINISTERS. Recommendation CM/Rec (2016)6 of the Committee of Ministers to member States on research on biological material of human origin (Adopted by the Committee of Ministers on 11 May 2016).

## 5.9 Publication of Results

Each beneficiary must ensure open access (free of charge, online access for any user) to all peer-reviewed scientific publications relating to their results, if this is compliant with national/regional funding regulations.

Funding recipients must ensure that all outcomes (publications, etc.) of transnational EJP RD projects include a proper acknowledgement of EJP RD and the respective national/regional funding partner organizations. This includes the display of the EJP RD logo when possible.

Unless the EC requests or agrees otherwise or unless it is impossible, any dissemination of results (in any form, including electronic) must:

1. display the EU emblem and
2. include the following text: "This project has received funding from (Name of funding agency) partner of the EJP RD. The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°825575"

When displayed together with another logo, the EU emblem must have appropriate prominence. For the purposes of the obligations under this Article, the beneficiary may use the EU emblem without first obtaining approval from the Agency. This does not however give it the right to exclusive use. Moreover, the beneficiary may not appropriate the EU emblem or any similar trademark or logo, either by registration or by any other means.

## 6. General Data Protection Regulation

### The following Data Privacy Notice applies

By submitting an application to the call JTC2023, applicants consent to the use, processing and retention of their data for the purposes of:

- processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller.
- administering any subsequent funding award.
- managing the Funding Party's relationship with them.
- analysing and evaluating the call;
- reporting to the European Commission/ Research Executive Agency (REA) on the Co-funded call.
- providing aggregate data to national and European surveys and analyses.
- complying with audits that may be initiated by the Funding Parties and the European Commission (or its agencies).

The members of the EJP RD consortium may share an applicant's data with third parties (some of which may be based outside the European Economic Area) in relation to the above activities including evaluators, auditors and the European Commission (or its agencies).

The members of the EJP RD consortia may link the data that applicants provide in the application with national, bibliographic or external research funding data which is available through public subscription-based databases (e.g. Scopus, Web of Science, etc.) or other national / open datasets. The members of the EJP RD consortia may also link the data that applicants provide in their application with future data that applicants provide as part of the ongoing management and reporting on a call award which may be awarded to them.

Data on Funding Parties including contact details of FC members and National Contact Points/Regional Contact Points are kept for the purpose of the call communication. The information will be published with prior consent of the respective management bodies.

## ANNEX 1: Country and Region-Specific Guidelines

### BELGIUM, FRENCH SPEAKING COMMUNITY, F.R.S.-FNRS

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Belgium
<b>Funding organisation</b>	Fund for Scientific Research – FNRS (F.R.S.-FNRS)
<b>Management organisation</b>	Fund for Scientific Research – FNRS (F.R.S.-FNRS)
<b>National contact person</b>	Dr. Florence Quist Phone: +32 (0)2 504 9351  Joël Groeneveld Phone: +32 (0)2 504 9270  E-mail: international@frs-fnrs.be
<b>Funding commitment</b>	0,2 Mio€
<b>Overheads</b>	“Overhead” is not an eligible cost. If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.
<b>Anticipated number of fundable research partners</b>	1
<b>Maximum funding per grant awarded to a partner</b>	200.000 €
<b>Eligibility of project duration</b>	Maximum 3 years. If the project involves the recruitment of a PhD student, the project duration of the F.R.S.-FNRS sub-project could be up to 4 years but should remain within the 200.000 € budget maximum (cf. <a href="#">PINT-Multi regulations</a> , art. III.3, second paragraph)
<b>Eligibility of a partner as a beneficiary institution</b>	All eligibility rules and criteria can be found in the <a href="#">PINT-Multi regulations</a> . It is <b>strongly advised</b> to contact the F.R.S.-FNRS prior to submission regarding the eligibility criteria.

Eligibility of costs, types and their caps	All eligibility rules and criteria can be found in the <a href="#">PINT-Multi regulations</a> . It is <b>strongly advised</b> to contact the F.R.S.-FNRS prior to submission regarding the eligibility criteria.
Conditions for PAO funding	Participating Belgian patients organizations could be financed via subcontracting, provided that the criterion for subcontracting detailed in the PINT-MULTI regulations are fulfilled (see art. III.3).
Submission of the proposal at the national level	<b>Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on <a href="#">e-space</a> within 5 working days after the general deadline of EJP RD call to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.</b>
Submission of other information at the national level	N/A
Submission of financial and scientific reports at the national level	Financial reporting must be submitted to the F.R.S.-FNRS
Further guidance	<a href="#">PINT-MULTI regulations</a> , <a href="#">e-space</a>

**CANADA, CIHR-IG**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Canada
<b>Funding organisation</b>	Canadian Institutes of Health Research, Institute of Genetics (CIHR-IG)
<b>National contact person</b>	<p><b>Jennifer Vineham</b>  <b>Phone: +1 343 552-2760</b>  <b>Email: <a href="mailto:jennifer.vineham@cihr-irsc.gc.ca">jennifer.vineham@cihr-irsc.gc.ca</a></b></p> <p><b>Etienne Richer</b>  <b>Email: <a href="mailto:Etienne.Richer@cihr-irsc.gc.ca">Etienne.Richer@cihr-irsc.gc.ca</a></b></p>
<b>Funding commitment</b>	<p>CIHR: CAD \$1,200,000,  Ataxia Canada: CAD \$450,000  Cystic Fibrosis Canada: CAD \$150,000  Total funding available: CAD \$1,800,000  CAD \$150,000 per year per project maximum.</p>
<b>Overheads</b>	Not an allowable cost.
<b>Anticipated number of fundable research partners</b>	3-4 projects
<b>Eligibility of project duration</b>	3 years
<b>Eligibility of a partner as a beneficiary institution</b>	
<b>Eligibility of costs, types and their caps</b>	<p><b>Eligibility of principal investigator or other research team member</b>  Academia, Clinical, Public Health  <a href="https://cihr-irsc.gc.ca/e/50805.html#g-3">https://cihr-irsc.gc.ca/e/50805.html#g-3</a></p> <p><b>Investigator (early career)</b>  An early career researcher (ECR) is a researcher within five years of the date of their first independent research-related appointment. Given that career progress for an ECR is particularly vulnerable to normal life circumstances, CIHR will adjust the eligibility window, as follows:</p>

	<ul style="list-style-type: none"> <li>• eligible leaves (e.g. maternity, parental, medical, family medical, bereavement) will extend ECR status (i.e. will not be counted towards the maximum) and are credited as twice the amount of time taken;</li> <li>• no adjustments are provided for professional leaves (e.g., training, sabbatical, administrative). No adjustments are provided for time spent on non-research related duties or for the pursuit of non-research related career activities.</li> </ul> <p><b>Eligibility of costs, types and their caps</b> <a href="https://www.nserc-crsng.gc.ca/InterAgency-Interorganismes/TAFA-AFTO/guide-guide_eng.asp">https://www.nserc-crsng.gc.ca/InterAgency-Interorganismes/TAFA-AFTO/guide-guide_eng.asp</a></p>
<b>Conditions for PAO funding</b>	Canadian patient advocacy organizations (PAOs) or patient representative are not eligible to participate in the role of Nominated Principal Applicant (NPA) nor Principal Applicant (PA). However, it is possible for a PAO to be represented by an individual in the role of co-applicant or collaborator. In this case, the NPA may request funds in their budget to support the activities of the PAO or patient representative on the project.
<b>Submission of the proposal at the national level</b>	Short application as per CIHR Funding Opportunity (link to follow). Summary of the applications potentially relevant for funding by Ataxia Canada or Cystic Fibrosis Canada will be made available to that organization to confirm relevancy of the proposals to their mandates.
<b>Submission of other information at the national level</b>	NA
<b>Submission of financial and scientific reports at the national level</b>	The Nominated Principal Applicant will be required to submit an electronic Final Report to CIHR. This online report will be made available to the Nominated Principal Applicant on ResearchNet at the beginning of the grant funding period and can be filled in as the research progresses.
<b>Further guidance</b>	NA

FRANCE, ANR

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

Country	France
Funding organisation	French National Research Agency (Agence Nationale de la Recherche –ANR) <a href="http://www.agence-nationale-recherche.fr">http://www.agence-nationale-recherche.fr</a>
National contact person	Health & Biology Department Agence Nationale de la Recherche –ANR 86 rue Regnault - 75013 Paris, France Dr Florence Guillot Dr Camille de Almeida Dr Ingrid Pfeifer Email: <a href="mailto:EJPRDcall@anr.fr">EJPRDcall@anr.fr</a>
Funding commitment	3.11 M€ Funding limits apply per partner for this call: Each partner may be granted up to <b>300 000 € as a coordinating partner</b> or <b>250 000 € as a non-coordinating partner</b> . The maximum amount that can be requested by French partners per project is 500 000 € The minimum funding amount per partner is 15 000 €.
Overheads	The ANR heading for “overheads” in the ANR funding breakdown is «frais d’environnement». 13,5% of the total eligible costs must be applied for if the partner belongs to a public research organisation (or other organisation funded at “marginal” costs), or up to 68% of the total personnel costs and 7% of other costs for partners funded at full economic cost (such as enterprises) (cf “règlement financier ”)
Anticipated number of fundable research partners	10-12
Eligibility of project duration	2-3 years
Eligibility of a partner as a beneficiary institution	<p><b>Eligible institutions:</b></p> <ul style="list-style-type: none"> <li>- Public research organisation or related-one<sup>†</sup> such as EPST, EPIC, universities, university hospitals, non-university research institutes, foundations (max. rate of support: 100% of marginal costs, for organisations funded at “marginal cost”)</li> <li>- Enterprises: large &amp; SMEs (max. rate of support: 45% of total costs for SMEs &amp; 30% for larger companies) Please consult <a href="https://anr.fr/fr/rf/">https://anr.fr/fr/rf/</a> for more details.</li> </ul> <p>Additional eligibility criteria:</p> <ul style="list-style-type: none"> <li>- The coordinator (if from a French organisation) must belong to a public research organisation.</li> </ul>

	<ul style="list-style-type: none"> <li>- ANR does not allow double applications nor provide double funding to finance projects or part of projects that have been funded through other national and international calls. ANR will cross-check the proposals submitted to ensure they have not been submitted to the ANR through other calls.</li> <li>- Countries subject to sanction(s) applicable to the field of research by the European Union are excluded from the current call. At the date of publication, the following countries are excluded: Russia, Belarus. This list is subject to change in the event of new sanctions decided by the European Union. Please consult « <i>Modalités pour les partenaires sollicitant une aide de l'ANR</i> » for more details on <a href="https://anr.fr/fr/appels/">https://anr.fr/fr/appels/</a>.</li> </ul>
<b>Eligibility of costs, types and their caps</b>	<p>Eligible costs include (but are not limited to) the following: personnel costs (for temporary contracts only for organisations funded at "coût marginal"); for temporary contracts; small equipment; consumables and animal costs; travel; and sub-contracting, if necessary, to carry out the proposed activities (sub-contracting costs max 50% of requested budget per partner).</p> <p>Eligible costs depend on the type of partner and consortium makeup. Please refer to the ANR Funding regulations for more details: <a href="https://anr.fr/fr/rf/">https://anr.fr/fr/rf/</a>.</p>
<b>Conditions for PAO funding</b>	<p>French patient organisations may participate in the Project as Partners or as service providers depending on the conditions of the collaboration. As Partners, they will be subject to the provisions of 2.2 of the ANR's Financial Regulations<sup>[1]</sup>; as a service provider of an entity subject to the rules of public procurement, the provisions of article L.2153-1 of the public procurement code apply.</p>
<b>Submission of the proposal at the national level</b>	<p>No. Please note that some funding agencies that request submission at national level may be made available upon request applications (pre-proposals and full proposals) after the publication of the funding decision (i.e. SRC).</p>
<b>Submission of other information at the national level</b>	<p>No. However, please contact the national contact point for the ANR to enquire about their eligibility before submitting a proposal. In the proposal, justification of all costs must be provided especially sub-contracting, other direct costs...</p>
<b>Submission of financial and scientific reports at the national level</b>	<p>Financial reporting: must be completed according to ANR regulations, and the funding contract that beneficiaries will have to sign.</p> <p>Scientific reports: individual scientific reports are not required. However, ANR funded partners should contribute to the project report to be submitted by the coordinator of the project to EJP RD. These reports will be the basis for validation of yearly advancements of the project by ANR.</p> <p>Consortium agreement signed by all consortium's members and a data management plan <b>must</b> be provided.</p>
<b>Further guidance</b>	<p><u>Règlement financier</u></p> <p>Please read the Modalities for applicants for this call on the ANR website, the <a href="#">financial rules</a> of ANR and the <a href="#">FAQ</a>.</p>

[1] Associations wishing to be partners must be categorised as a company or research organisation. If they are categorised as a company, only those with their real head office in a European Union country and with an establishment or branch in France may be beneficiaries of ANR grants. If they are categorised as a research organisation, only those with their main establishment in France may be beneficiaries of ANR grants (see <https://anr.fr/RE>.)

**GERMANY, BMBF/PT-DLR**

**It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal**

<b>Country</b>	Germany
<b>Funding organisation</b>	German Federal Ministry for Education and Research (BMBF) <a href="http://www.gesundheitsforschung-bmbf.de">www.gesundheitsforschung-bmbf.de</a>
<b>Management organisation</b>	German Aerospace Center, DLR Project Management Agency (DLR-PT) <a href="http://www.pt-dlr.de">www.pt-dlr.de</a>
<b>National contact person</b>	<p><b>German Aerospace Center</b> DLR Project Management Agency   Health   Division Clinical Research, University Medicine, Digital Health Heinrich-Konen-Straße 1 53227 Bonn Germany</p> <p>Dr. Katarzyna Saedler</p> <p>Dr. Michaela Fersch</p> <p>Dr. Ralph Schuster</p> <p>+49228-38212453 SelteneErkrankungen@dlr.de</p>
<b>Funding commitment</b>	3 Mio€
<b>Overheads</b>	Overheads refer to "Gemeinkosten" (applicable for Helmholtz-centres and Fraunhofer-Society) as well as "Projektpauschale" (applicable for universities and university hospitals). The "Projektpauschale" generally will amount to 20% of the applied total project expenditure. For further information on the "Projektpauschale" please refer to <a href="https://foerderportal.bund.de/easy/module/easy_formulare/download.php?datei=179">https://foerderportal.bund.de/easy/module/easy_formulare/download.php?datei=179</a> (Pos. 0865) or contact the German national contact point for this EJP RD call.
<b>Anticipated number of fundable research partners</b>	Partners in about 7 projects.

<b>Maximum funding per grant awarded to a partner</b>	The funding request should not exceed 450.000 EUR per consortium including overheads (i.e. if two German partners participate in a consortium, the sum of funding requested by both groups should not exceed 450.000 EUR). The direct involvement of patients or their representatives in the consortium via subcontracting can be supported by an additional 30.000 € (including taxes, plus overhead for the subcontracting institution if applicable).
<b>Eligibility of project duration</b>	Maximum 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, non-university public research institute, industry, patient organization
<b>Eligibility of costs, types and their caps</b>	Personnel, consumables, animals, subcontracts, equipment, travels, documentation, overheads according to national regulations.
<b>Conditions for PAO funding</b>	Participating German patient organizations can be funded either directly or through subcontracting by a research partner. The direct involvement of patients or their representatives in the consortium via subcontracting can be supported by an additional 30.000 € (including taxes, plus overhead for the subcontracting institution if applicable).
<b>Submission of the proposal at the national level</b>	No
<b>Submission of other information at the national level</b>	Yes, for proposal selected for funding
<b>Submission of financial and scientific reports at the national level</b>	Yes, according to national regulations.

## GERMANY, DFG

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Germany
<b>Funding organisation</b>	German Research Foundation (DFG) <a href="http://www.dfg.de">www.dfg.de</a>
<b>National contact person</b>	<b>Deutsche Forschungsgemeinschaft (DFG)</b> Kennedyallee 40 53175 Bonn Germany  Dr. Katja Hartig Tel. +49 (228) 885-2359 <a href="mailto:katja.hartig@dfg.de">katja.hartig@dfg.de</a> , <a href="mailto:katja.grossmann@dfg.de">katja.grossmann@dfg.de</a>
<b>Funding commitment</b>	1.5 Mio€
<b>Overheads</b>	
<b>Anticipated number of fundable research partners</b>	tbd
<b>Maximum funding per grant awarded to a partner</b>	The funding request should not exceed 450,000 EUR per consortium including overheads (i.e. "Programmpauschale" of 22%). The same applies if two German partners participate in a consortium.
<b>Eligibility of project duration</b>	Maximum 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Legal body: university, university hospital, non-university public research institute: Industry is not eligible; some restrictions for non-university public research institutes; for further information see <a href="http://www.dfg.de/formulare/55_01/">http://www.dfg.de/formulare/55_01/</a>
<b>Eligibility of costs, types and their caps</b>	Personnel, consumables, animals, subcontracts, equipment, travels, documentation according to national regulations. Overheads : The "Programmpauschale" will generally amount 22% of the total project expenditure. See <a href="http://www.dfg.de">www.dfg.de</a>
<b>Submission of the proposal at the national level</b>	After proposal submission at the EJP RD-portal the proposal will be assigned to DFG and BMBF by the management organisations. Proposals assigned to the DFG will then have to be uploaded at the ELAN-portal of the DFG.

<b>Submission of other information at the national level</b>	Yes, for proposal selected for funding
<b>Submission of financial and scientific reports at the national level</b>	Yes, according to national regulations.
<b>Further guidance</b>	<a href="http://www.dfg.de/en/research_funding/programmes/individual/research_grants/index.html">http://www.dfg.de/en/research_funding/programmes/individual/research_grants/index.html</a>

### HUNGARY, NKFIH

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Hungary
<b>Funding organization</b>	Ministry of Culture and Innovation
<b>Management organization</b>	National Research, Development and Innovation Office (NKFIH) <a href="http://nkfi.gov.hu/">http://nkfi.gov.hu/</a> ; <a href="http://nkfi.gov.hu/for-the-applicants">http://nkfi.gov.hu/for-the-applicants</a>
<b>National contact person</b>	National Research, Development and Innovation Office, Kéthly Anna tér 1, Budapest, H-1077, Hungary Dr. Előd Nemerkenyi Assistant of International Affairs, Department of Research and Development, NKFIH Phone: +36 1 8963987 E-mail: <a href="mailto:elod.nemerkenyi@nkfi.gov.hu">elod.nemerkenyi@nkfi.gov.hu</a> Dr. Gábor Tóth head of unit, Unit for Medical and Biological Sciences, Department of Research and Development, NKFIH Phone: +36 1 8961727 E-mail: <a href="mailto:gabor.toth@nkfi.gov.hu">gabor.toth@nkfi.gov.hu</a>
<b>Funding commitment</b>	300.000 €
<b>Overheads</b>	10% of the total costs of the project. Applicants should consult NKFIH '2019-2.1.7-ERA-NET' call regulations for details.
<b>Anticipated number of fundable research partners</b>	2
<b>Maximum funding per grant awarded to a partner</b>	Up to 150.000 €. If more than one partner applies from Hungary, their total requested funding should not exceed 150.000 euros.
<b>Eligibility of project duration</b>	Up to 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Universities, academic and public research institutions, public health institutions (university or non-university hospitals and clinics). An SME or a non-profit organization is eligible if its main activity is research according to its deed of foundation [category: 'research and knowledge-dissemination organisation' – see <i>Commission Regulation (EU) No. 651/2014 Article 2 (83)</i> ]. All eligibility rules and criteria can be found in the '2019-2.1.7-ERA-NET' call regulations. It is strongly advised to contact NKFIH prior to submission regarding the eligibility criteria.
<b>Eligibility of costs, types and their caps</b>	100% of eligible research-related costs for basic (exploratory) research. The maximum indirect costs (overhead) are 10% of total costs. The maximum funding of 150.000 € per project includes the overhead. Detailed list of eligible costs (basically personnel, consumables, animals, equipment, travel, subcontracts, overhead) and guidelines to prepare the budget plan can be found in the call text and guideline of NKFIH '2019-2.1.7-ERA-NET'

	call ( <a href="https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net">https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net</a> ).
<b>Eligibility of principal investigator</b>	The principal investigator must hold a Ph.D., D.Sc., or equivalent degree and be employed by an eligible institution. Researchers cannot participate in more than one proposal submitted to the same joint transnational call.
<b>Conditions for PAO funding</b>	No funding of PAOs.
<b>Submission of the proposal at the national level</b>	Hungarian applicants are strongly requested to contact NKFIH to confirm eligibility before submitting a proposal. Basic information should be provided to NKFIH, including applicant name and institution, as well as an estimation of the requested budget. Upon the EJP RD funding decision a proposal should be formally submitted to NKFIH in its electronic proposal system (EPTK). This is necessary for funding and managing the project by NKFIH.
<b>Submission of financial and scientific reports at the national level</b>	Yes, according to national regulations.

**IRELAND, HRB**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country / Region</b>	Ireland
<b>Funding organisation</b>	Health Research Board
<b>National contact person</b>	Siobhán Hackett <a href="mailto:eujointprogrammes@hrb.ie">eujointprogrammes@hrb.ie</a>
<b>Funding commitment</b>	Up to €370,000 in total
<b>Overheads</b>	Yes, must be included within the maximum budget request of €370,000
<b>Anticipated number of fundable research partners</b>	1–2
<b>Maximum funding per grant awarded to a partner</b>	€370,000
<b>Eligibility of project duration</b>	Up to 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Partners must be based in a HRB approved <a href="#">Host Institution</a> .
<b>Eligibility of principal investigator or other research team member</b>	<p>The Lead Applicant must:</p> <ul style="list-style-type: none"> <li>Hold a post (permanent or a contract that covers the duration of the award) in a HRB recognised Host Institution in the Republic of Ireland (the “Host Institution”) as an independent investigator. For clinicians, an adjunct position in a HRB recognised Host Institution is acceptable.</li> </ul> <p><b>OR</b></p> <p>Be an individual who will be recognised by the Host Institution upon receipt of an award as an independent investigator who will have a dedicated office and research space for the duration of award, for which they will be fully responsible. The Irish Lead Applicant does not necessarily need to be employed by the Host Institution at the time of the application submission.</p> <ul style="list-style-type: none"> <li>Show evidence of achievement as an independent researcher in their chosen research field by: <ul style="list-style-type: none"> <li>i. Demonstrating a record of research output, with at least three publications of original research in peer reviewed journals.</li> </ul> </li> </ul>

	<p>ii. Demonstrating record of independence by showing that they have secured at least one peer-reviewed research grant for a research project/s, as either the Lead Applicant or a Co-Applicant. Funding received for travel to seminars/conferences and/or small personal bursaries will not be considered in this regard.</p> <p>iii. Show evidence that they possess the capability and authority to manage and supervise the research team.</p> <p>Early Career Researchers must have:</p> <ul style="list-style-type: none"> <li>• A PhD or have been granted PhD equivalence by the HRB before submission.</li> <li>• At least four years and up to seven years active post PhD (or equivalent) research experience.</li> </ul> <p>Please refer to full guidance on <a href="#">HRB's scheme page</a> for further information.</p>
<p><b>Eligibility of costs, types and their caps</b></p>	<p>Funding available is inclusive of overheads and pension contributions and will cover research related costs including salary for research staff, running costs, FAIR data management costs, equipment (up to €10,000) and dissemination costs, and overheads contributions</p> <p>Overheads are applied in accordance with the HRB Policy on Overhead Usage, the HRB will contribute to the indirect costs of the research through an overhead payment of 30% of Total Direct Modified Costs (TDMC excludes student fees, equipment and capital building costs) for <b>laboratory or clinical-based research</b> and 25% of Total Direct Modified Costs of <b>desk-based research</b>.</p> <p>Irish Partner(s) are not eligible for HRB funding for:</p> <ul style="list-style-type: none"> <li>• Proposals seeking to evaluate a pilot or feasibility study.</li> <li>• Proposals seeking to evaluate a definitive intervention.</li> <li>• Proposals involving basic biomedical research.</li> <li>• Research intended to create human embryos solely for the purposes of research or for the purposes of stem cell procurement, including by means of somatic cell nuclear transfer.</li> </ul>
<p><b>Submission of other information at the national level</b></p>	<p>For full proposal stage: Irish partners are asked to provide a list of <b>deliverables and supplementary budget information to the HRB</b>. This will expedite contract negotiations with HRB in the case of successful consortia with applicants from Ireland. Relevant templates will be provided by the HRB.</p>
<p><b>Submission of financial and scientific reports at the national level</b></p>	<p>Annually</p>
<p><b>Further guidance</b></p>	<p>Please refer to HRB's guidance on the <a href="#">HRB scheme page</a> or contact the HRB at the contact address above for full information.</p>

**ISRAEL, CSO-MOH**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Israel
<b>Funding organization</b>	Chief Scientist office, Ministry of Health (CSO-MOH) <a href="http://www.health.gov.il/">http://www.health.gov.il/</a>
<b>National contact person</b>	Dr. Irit Allon Phone: +972-2-5082167 Email: <a href="mailto:Irit.allon@moh.health.gov.il">Irit.allon@moh.health.gov.il</a>
<b>Funding commitment</b>	Up to 300.000 Euros
<b>Overheads</b>	10% of the entire project
<b>Anticipated number of fundable research partners</b>	Up to 2
<b>Maximum funding per grant awarded to a partner</b>	Up to 140,000 Euros (Additional EUR 20,000 for coordination of a consortium)
<b>Eligibility of a partner as a beneficiary institution</b>	Position in a university, research center or hospital. Research authority must approve position prior to submission.
<b>Eligibility of costs, types and their caps</b>	Materials and consumables; Travel (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead -10%
<b>Conditions for PAO funding</b>	No funding of PAOs
<b>Submission of the proposal at the national level</b>	<b>Prior to submission of the pre-proposal to EJP RD, Israeli researchers need to submit to CSO-MOH an <a href="#">IL abstract</a> approved by their research authority including budget distribution.</b> The IL abstract will contain the project title, acronym and partners and will <b>elaborate the part of the Israeli group in the project</b> . IL abstract is <u>not</u> the abstract of the entire project. No submission of IL abstract can result in declaration of the consortium as ineligible. Researchers cannot apply for more than one grant from any ERA-Net funded by CSO-MOH or submit more than one proposal to any programme.
<b>Further guidance</b>	If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later.

Please see detailed instructions at [www.health.gov.il/research-fund](http://www.health.gov.il/research-fund)

**ITALY, IT-MoH**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Italy
<b>Funding organisation</b>	Italian Ministry of Health <a href="http://www.salute.gov.it">www.salute.gov.it</a>
<b>Management organisation</b>	Italian Ministry of Health - General Directorate for Innovation & Research in Healthcare
<b>National contact person</b>	Italian Ministry of Health  Gaetano Guglielmi <a href="mailto:g.guglielmi@sanita.it">g.guglielmi@sanita.it</a>  Chiara Ciccarelli +39 06 5994 3919 <a href="mailto:c.ciccarelli@sanita.it">c.ciccarelli@sanita.it</a>  Simona Bifulchi <a href="mailto:s.bifulchi@sanita.it">s.bifulchi@sanita.it</a>
<b>Funding commitment</b>	1.5 M€
<b>Overheads</b>	Overhead (maximum 10% of the requested fund).
<b>Additional documents required</b>	The Italian Ministry of Health will check for the pre-eligibility of the applicants before the submission of the pre-proposals to speed up the eligibility check process. To this end, it is mandatory that the applicants fill out and return a pre-eligibility check form (sent to all IRCCSs) using the WFR System (Code ER) before the submission of their pre-proposals to the Joint Call Secretariat. The form, completed and duly signed, has to be returned at least 10 working days before the pre-proposal submission deadline. Applicants will receive a written notification of their eligibility status. The pre-eligibility form can be downloaded here: <a href="http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf">http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf</a> ; <a href="http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf">http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf</a>

<b>Maximum funding per grant awarded to a partner</b>	Max. 400.000 EUR per consortium (i.e., if two IRCCSs participate in a consortium, the sum of funding requested by both groups must not exceed 400.000 EUR)
<b>Eligibility of project duration</b>	Maximum 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Only Scientific Institutes for Research, Hospitalisation and Healthcare (IRCCS) are eligible. No academic and industrial partners are eligible.
<b>Eligibility of costs, types and their caps</b>	<p>Only the costs generated throughout the duration of the project can be eligible.</p> <p>Personnel (only ad hoc contracts/consultants/fellowships, max 50% of the requested fund)</p> <p>Travel costs and subsistence allowances (max 10% of the requested fund) only if associated with training activities linked to the project</p> <p>Equipment (rent/leasing only, no limits)</p> <ul style="list-style-type: none"> <li>• consumables (no limits)</li> <li>• dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund)</li> </ul> <p>Data handling and analysis (no limits) Transfer of eligible funds abroad for leasing, sub-contracts, etc. is not allowed</p> <p>Sub-contracts are not allowed except in case of absolute necessity and to fund Italian PAOs (see below); the costs for sub contracts need to be authorized by the It MoH in advance, following a detailed request. In this case, the pre-eligibility must be requested 20 working days before the deadline of the call.</p>
<b>Conditions for PAO funding</b>	<p>Italian PAOs can be funded as a sub-contractor of the IRCCS if they fulfil the eligibility criteria of the EC. The maximum cost eligible for a sub-contract is 25.000 Euros (from the IRCCS Budget).</p> <p>Italian PAOs can still participate in Consortia as "Collaborators" with their own funds</p>
<b>Submission of the proposal at the national level</b>	No
<b>Submission of other information at the national level</b>	After the joint EJP RD 2023 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). The funding of this projects is under the Ricerca Corrente IRCCS rules.

<b>Submission of financial and scientific reports at the national level</b>	Submission of an annual scientific and financial reports at the national level could be required according to the rules of the Ministry of Health Ricerca Corrente - IRCCS
<b>Further information</b>	The pre-eligibility form can be downloaded here: <a href="http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf">http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf</a>

**ITALY, LOMBARDY, FRRB**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Italy
<b>Funding organization</b>	Fondazione Regionale per la Ricerca Biomedica - Regional Foundation for Biomedical Research (FRRB)
<b>National contact person</b>	Paola Bello, Marcello De Amico Via Taramelli 12, 20124 – Milano Tel: +39 02 67650174 <a href="mailto:bandi@frb.it">bandi@frb.it</a>
<b>Funding commitment</b>	€ 1.500.000,00
<b>Overheads</b>	Up to 20% flat rate calculated on direct costs – Subcontracting costs excluded.
<b>Anticipated number of fundable research partners</b>	3-4
<b>Maximum funding per grant awarded to a partner</b>	Maximum € 500,000 <b>per project. MAXIMUM TWO PARTNERS FROM LOMBARDY PER PROJECT.</b> (In case of wo Lombardy partners in the same consortium, the amount of 500,000 will be shared)
<b>Eligibility of a partner as a beneficiary institution</b>	<p><b>Eligible applicants:</b></p> <ol style="list-style-type: none"> <li>Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care)</li> <li>Public Health Care Providers (ASST)</li> <li>Agenzie di Tutela della Salute (ATS),</li> <li>Azienda Regionale Emergenza Urgenza (AREU),</li> <li>Universities - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB</li> <li>Research Institutes - only in in partnership with one of the organizations above (1,2,3,4) located in Lombardy and requesting funding to FRRB</li> </ol> <p>Please refer to the definition of research institutes and organisations on the FRRB webpage <a href="https://www.frb.it/it/ejp-jtc-2023">https://www.frb.it/it/ejp-jtc-2023</a></p> <p>All applicants must be located in Lombardy and their activities should take place in Lombardy. Enterprises and for-profit Organisation are <b>NOT</b> eligible.</p>
<b>Eligibility of costs, types and their caps</b>	<p>Direct costs:</p> <ul style="list-style-type: none"> <li>Personnel (for public IRCCS and ASST, ATS and AREU, <b>ONLY</b> staff recruited specifically on the project). Personnel costs of PIs who have a permanent contract (<i>contratto indeterminato</i>) with their own organisation are NOT eligible.</li> </ul>

	<ul style="list-style-type: none"> <li>• Consumables, animals purchase, maintenance and breeding.</li> <li>• Equipment (on hire or eligible amortization rate).</li> <li>• Travel: max 10% of the total direct costs (<i>overheads and subcontracting costs excluded</i>)</li> <li>• Publications (only open access): max 5% of the total direct costs (<i>overheads and subcontracting costs excluded</i>).</li> <li>• Overheads: 20% flat rate calculated on direct costs (<i>Subcontracting costs excluded from this calculation</i>).</li> <li>• Other direct costs: please include here other costs, including those related to patient involvement (insurance, reimbursement, etc.).</li> <li>• Subcontracting: max 20% of the total direct costs (<i>overheads costs excluded</i>)</li> </ul> <p>FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the "Subcontracting" category will be eligible up to a maximum of € 8.000. Only costs generated over the lifetime of the project will be considered eligible.</p> <p><b>Rules regarding the Principal Investigator (PI):</b></p> <ol style="list-style-type: none"> <li>1. A Principal Investigator (PI) cannot simultaneously hold more than one FRRB grant. PIs who are currently FRRB grant holders cannot apply to a new JTC unless their project is closed before the deadline of the new JTC pre-proposals. A project is considered closed when the final financial and scientific reports have been sent to FRRB. This rule applies only to PIs, not to team members.</li> <li>2. Personnel costs of PIs who have a permanent contract with their own organisation are NOT eligible.</li> </ol>
<p><b>Conditions for PAO funding</b></p>	<p>PAO are not eligible for FRRB funding</p>
<p><b>Submission of the proposal at the regional level</b></p>	<p>It is not necessary to send the proposal to FRRB. However, FRRB requires a <b>Pre-eligibility form</b>. According to internal procedures, Regional Foundation for Biomedical Research (FRRB) will carry out an <b>eligibility check</b> to potential applicants prior to the submission of the pre-proposals.</p> <p>The eligibility check will be based on the verification of a dedicated form ("<b>Pre-eligibility form</b>"), also available on the FRRB institutional website, to be returned, by email, to FRRB (<a href="mailto:bandi@frb.it">bandi@frb.it</a>), duly completed and signed by the Principal Investigator at least 10 working days before the pre-proposal submission deadline.</p> <p>FRRB will provide feedback on the "<i>Pre-eligibility form</i>", <b>ONLY</b> in case of major non-eligibility issues.</p> <p>Principal Investigators (PIs) who submit a proposal without sending the "<i>Pre-eligibility form</i>" to FRRB beforehand will be automatically excluded.</p> <p>In addition, FRRB provides an excel sheet to help applicants abide by FRRB funding rules. This form is meant to support the PIs in the elaboration of the proposal budget, but it does not need to be sent to FRRB.</p>

	<p>Information and instructions on how to fill the Pre-Eligibility check form will be published on the dedicated webpage <a href="https://www.frrb.it/it/ejp-jtc-2023">https://www.frrb.it/it/ejp-jtc-2023</a></p> <p>Following the award, Lombardy beneficiaries will be requested to submit annual scientific and financial reports.</p>
<b>Further guidance</b>	<p>Administrative and financial guidelines will be provided by FRRB in due time to the contact persons of the funded organisations.</p>

**ITALY, TUSCANY, RT/TuscReg**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country / Region</b>	Italy
<b>Funding organisation</b>	Tuscany Region <a href="http://www.regione.toscana.it/">http://www.regione.toscana.it/</a>
<b>Regional contact person</b>	Donatella Tanini Phone : +39 055 4383256  Teresa Vieri Phone : +39 055 4383289 Email: <a href="mailto:ejprare@regione.toscana.it">ejprare@regione.toscana.it</a>  Office for Health Research and investments, Directorate for Health, welfare and social cohesion Tuscany Region
<b>Funding commitment</b>	Up to 300.000 euros
<b>Overheads</b>	Up to 10% of the direct cost of the project, intended to cover the general cost of the institution that hosts the research team.
<b>Anticipated number of fundable research partners</b>	2-3
<b>Maximum funding per grant awarded to a partner</b>	Up to 300.000 euros Maximum € 300,000 per project. MAXIMUM TWO PARTNERS FROM TUSCANY PER PROJECT. (If there are two Tuscany partners in the same consortium, the amount of 300,000 will be shared)
<b>Eligibility of project duration</b>	Up to 3 years
<b>Eligibility of a partner as a beneficiary institution</b>	A. Authorities of the Tuscany Health Service-SST (Local Health Authorities, University Hospitals, including IRCCS AOU Meyer) and the SST bodies that carry out institutional research activities (Fondazione Toscana Gabriele Monasterio and ISPRO Institute for Study, Prevention and Networking Oncology) located in the territory of Tuscany.  B. Universities and other research institutes located in the territory of Tuscany.

	<p><b>NB:</b> Institutions referring to point B. are eligible only in partnership with institutions referring to point A.</p>
<p><b>Eligibility of principal investigator or other research team member</b></p>	<p>The Principal Investigator must be affiliated to one of the eligible bodies</p>
<p><b>Eligibility of costs, types and their caps</b></p>	<p>Only costs generated over the lifetime of the project will be considered eligible.</p> <ul style="list-style-type: none"> <li>- Personnel (ad hoc temporary contracts ONLY);</li> <li>- Consumables (no limit);</li> <li>- Equipment (on hire/leasing or eligible amortisation rate ONLY);</li> <li>- Travel (Up to 10% of the requested fund) Travel expenses and subsistence allowances associated with activities only linked to the project;</li> <li>- Other direct costs :             <ul style="list-style-type: none"> <li>• dissemination of results (publications, organization of meetings/workshops etc.- up to 5% of the requested fund);</li> <li>• data handling and analysis (no limit)</li> <li>• patients costs</li> </ul> </li> <li>- subcontracting (up to 20% of the direct costs of the projects)</li>   <li>- <i>Overheads</i> (Up to 10% of the direct cost of the project excepted subcontracting).</li> </ul>
<p><b>Conditions for PAO funding</b></p>	<p>PAO cannot be directly funded by Tuscany Region in the framework of this call.</p>
<p><b>Submission of the proposal at the regional level</b></p>	<p>Yes</p> <p><b>Tuscany Region will grant an eligibility clearance to the potential applicants prior to the submission of their pre-proposals.</b></p> <p>The eligibility check will be performed by Tuscany Region offices after receiving a dedicated form (available on Tuscany Region institutional web-site or on request to <a href="mailto:ejprare@regione.toscana.it">ejprare@regione.toscana.it</a>) duly filled and signed by the Tuscan Principal Investigator and by the legal representative of the beneficiary <b>The form should be sent to Tuscany Region (<a href="mailto:ejprare@regione.toscana.it">ejprare@regione.toscana.it</a>), at least, 10 working days before the pre-proposal submission deadline.</b></p>

<b>Submission of other information at the regional level</b>	No
<b>Submission of financial and scientific reports at the regional level</b>	Yes/Submission of intermediate/final scientific and financial reports at the regional level could be required according to regional agreement
<b>Further guidance</b>	Financial guidelines: Decreto dirigenziale n. 20197 del 19.11.2021 ( <a href="http://www301.regione.toscana.it/bancadati/atti/DettaglioAttiD.xml?codprat=2021AD00000022801">http://www301.regione.toscana.it/bancadati/atti/DettaglioAttiD.xml?codprat=2021AD00000022801</a> )

## ITALY, FTELE

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Italy
<b>Funding organization</b>	Fondazione Telethon (FTELE) – www.telethon.it
<b>National contact person</b>	Carmen Fotino Via Varese 16 b, 00185, Roma Tel: +39 02 202217256 telethonscience@telethon.itmailto:bandi@frrb.it
<b>Funding commitment</b>	€ 600.000,00
<b>Overheads</b>	Up to 10% flat rate calculated on direct costs
<b>Anticipated number of fundable research partners</b>	3-4
<b>Maximum funding per grant awarded to a partner</b>	Maximum € 200,000 <b>per project. MAXIMUM ONE PARTNER + ONE PAO PER PROJECT.</b> (In case the PAO is involved, the amount of 200,000 will be shared)
<b>Eligibility of a partner as a beneficiary institution</b>	<p><b>Eligible applicants:</b></p> <ol style="list-style-type: none"> <li>1. Italian not for profit research institutions</li> <li>2. Not for profit Patients advocacy organizations (PAO)</li> </ol> <p>Enterprises, Scientific Institutes for Research, Hospitalisation and Healthcare (IRCCS), Telethon Intramural Institutes and for-profit Organisation are <b>NOT</b> eligible. Moreover Public Health Care Providers (ASST), Agenzie di Tutela della Salute (ATS), Azienda Regionale Emergenza Urgenza (AREU) of Lombardy Region are <b>NOT</b> eligible. Also Authorities of the Tuscany Health Service-SST (Local Health Authorities, University Hospitals) and the SST bodies that carry out institutional research activities (Fondazione Toscana Gabriele Monasterio and ISPRO Institute for Study, Prevention and Networking Oncology) located in the territory of Tuscany are <b>NOT</b> eligible.</p>
<b>Eligibility of principal investigator or other research team member</b>	The Principal Investigator must be affiliated to one of the eligible bodies.
<b>Eligibility of costs, types and their caps</b>	<p><b>Eligible costs:</b></p> <ul style="list-style-type: none"> <li>• Personnel - Personnel costs of members of the staff who do not have a permanent contract with their own organisation.</li> </ul>

	<ul style="list-style-type: none"> <li>• Consumables.</li> <li>• Equipment up to 22.500 euro per project of which maximum 2.500 euro for IT equipment.</li> <li>• Travel: max 3.000 euro per year only if associated with training or activities linked to the project</li> <li>• Publications</li> <li>• Other direct costs: please include here other costs such as ethical committee fees, insurance, patients or experts reimbursement, organization of project meetings and trainings, etc.</li> <li>• Subcontracting</li> <li>• Overheads: 10% flat rate calculated on direct costs.</li> </ul> <p>Only costs generated over the lifetime of the project will be considered eligible.</p> <p><b>Not eligible costs:</b></p> <ul style="list-style-type: none"> <li>• Personnel costs of PIs and members of the staff who have a permanent contract (<i>contratto a tempo indeterminato</i>) with their own organization</li> <li>• Salary, travel and other expenses related to sabbatical year</li> <li>• Subscription to research and scientific societies</li> <li>• Organization of meetings and workshops outside the projects (not including meetings with project partners)</li> <li>• Construction, alteration, maintenance, lab furnishing, rental of buildings or building spaces and utilities, fax and telephone costs</li> <li>• Major basic equipment such as incubators, hoods, -80°C freezers.</li> </ul>
<b>Conditions for PAO funding</b>	PAO are eligible for FTELE funding only in partnership with an Italian not for profit research institutions
<b>Submission of financial and scientific reports at FTELE</b>	Yes/Submission of intermediate and final financial reports as well as final scientific report could be required
<b>Further guidance</b>	<p>Administrative and financial guidelines will be published on FTELE website (<a href="http://www.telethon.it">www.telethon.it</a>) by the date of publication of the JTC 2023.</p> <p>FTELE will perform a Direct Management of funds at no additional costs on the basis of a contract conferring a mandate without representation and FTELE will be appointed as data processor by the Host Institution. Exceptionally, and for valid and justified reasons, the Host Institution can ask FTELE the possibility to manage itself exclusively the funds for personnel and overheads (External Management).</p>

**LITHUANIA, LMT**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Lithuania
<b>Funding organization</b>	Lietuvos mokslo taryba (LMT) / Research Council of Lithuania <a href="http://www.lmt.lt">http://www.lmt.lt</a>
<b>National contact person</b>	<b>Dr. Živilė Ruželė</b> <b>Phone:</b> (+370) 676 14383, <b>E-mail:</b> <a href="mailto:zivile.ruzele@lmt.lt">zivile.ruzele@lmt.lt</a>
<b>Funding commitment</b>	0.3M€
<b>Overheads</b>	Up to 20 % from all direct costs-
<b>Anticipated number of fundable research partners</b>	2
<b>Maximum funding per grant awarded to a partner</b>	100-150K€ (up to 100K€ for consortium partner or up to 150K€ for coordinator)
<b>Eligibility of a partner as a beneficiary institution</b>	Eligible for funding institutions are Lithuanian research and higher education institutions included in the Register of Education and Research institutions and public healthcare institutions. Beneficiary institution manage the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable 'project partner' means public or private legal entity that, together with the eligible institution, created the conditions for project implementation).
<b>Eligibility of costs, types and their caps</b>	Only costs generated during the lifetime of the project, related to project are eligible: staff, travel, consumables, subcontracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 20 % from- direct costs ).
<b>Conditions for PAO funding</b>	PAO can be a subcontractor or a 'project partner' of the eligible beneficiary institution (see section Eligibility of a partner as a beneficiary institution)
<b>Submission of the proposal at the national level</b>	No
<b>Further guidance</b>	Further information: <a href="https://www.lmt.lt/lt/mokslo-finansavimas/era-net-ir-kitos-koordinavimo-veiklos/europos-jungtine-programa-retos-ligos/3033">https://www.lmt.lt/lt/mokslo-finansavimas/era-net-ir-kitos-koordinavimo-veiklos/europos-jungtine-programa-retos-ligos/3033</a>

The proposals are submitted by the researcher(s) together with the eligible beneficiary institution. The beneficiary institution employs the principal investigator to work in the project and his workload must be at least 20 hours multiplied by the number of months to execute the project. Hourly rates approved by the Chairman of the Lithuanian Research Council must be applied for the personnel costs. All other general rules for competitive funding of Research Council of Lithuania apply:  
<https://www.e-tar.lt/portal/lt/legalAct/0a8bead0577611e9975f9c35aedfe438/asr>

**LUXEMBURG, FNR**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country / Region</b>	Luxembourg
<b>Funding organisation</b>	Luxembourg National Research Fund - FNR <a href="http://www.fnr.lu">www.fnr.lu</a>
<b>National contact person</b>	Dr. Sean Sapcariu 2, avenue de l'Université L-4365 Esch-sur-Alzette Telephone: +352 691 362 831 Email: <a href="mailto:sean.sapcariu@fnr.lu">sean.sapcariu@fnr.lu</a>
<b>Funding commitment</b>	0,30 M€
<b>Overheads</b>	
<b>Anticipated number of fundable research partners</b>	2 research partners
<b>Maximum funding per grant awarded to a partner</b>	The maximum funding cannot be larger than the funding commitment of the country
<b>Eligibility of project duration</b>	3 years
<b>Eligibility of a partner as a beneficiary institution</b>	Beneficiary institutions must be accredited by the Ministry in charge of public sector research. See website for details ( <a href="https://www.fnr.lu/fnr-beneficiaries/">https://www.fnr.lu/fnr-beneficiaries/</a> ).
<b>Eligibility of principal investigator or other research team member</b>	Principle Investigators must follow the following guidelines: ( <a href="http://storage.fnr.lu/index.php/s/g4OPmRwEYhYwRkZ/download">http://storage.fnr.lu/index.php/s/g4OPmRwEYhYwRkZ/download</a> ) <ol style="list-style-type: none"> <li>1. He/she must have a proper employment contract with the eligible beneficiary institution at the starting date of the project.</li> <li>2. The employment contract must last for the full duration of the research project.</li> <li>3. He/she must be an experienced researcher who holds a doctoral degree at the date of the submission of the proposal.</li> </ol>
<b>Additional eligibility criteria</b>	Luxembourgish principal investigators cannot be involved in more than 2 proposals submitted to this call.

<b>Eligibility of costs, types and their caps</b>	<p>Personnel costs; Consumables; Equipment (only depreciation costs); Travel (according to travel plan); Subcontracting (up to 25% of direct costs - needs detailed justification, includes all external services, project core activities cannot be subcontracted); Indirect costs</p> <p>Please see INTER application guidelines for more information (<a href="https://www.fnr.lu/funding-instruments/inter/">https://www.fnr.lu/funding-instruments/inter/</a>)</p>
<b>Conditions for PAO funding</b>	<p>FNR can fund PAOs which are eligible beneficiaries of FNR funding. For further information, please contact the FNR.</p>
<b>Submission of the proposal at the national level</b>	<p>All joint applications must also be submitted to the FNR by the Luxembourg-based scientist, along with the FNR INTER documents. This must be done no later than 5 days after the lead agency deadline, and must be done via the FNR Online Grant Management System.</p>
<b>Submission of other information at the national level</b>	<p>The FNR requires the following other documents to be submitted to the FNR's grant management system :</p> <ul style="list-style-type: none"> <li>- INTER Budget form, INTER Project plan, Gantt Chart</li> </ul>
<b>Submission of financial and scientific reports at the national level</b>	<p>The FNR expects annual reports and a final report for all projects funded through this call.</p>
<b>Further guidance</b>	<p><a href="https://www.fnr.lu/fnr-international-cooperation/">https://www.fnr.lu/fnr-international-cooperation/</a></p>

**POLAND, NCBR**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Poland
<b>Funding organization</b>	National Centre for Research and Development (NCBR)
<b>National contact person</b>	Dr Marcin Chmielewski Department for International Cooperation, ul. Nowogrodzka 47a, 00-695 Warszawa, Poland Tel: (+48) 22 39 07 109, (+48) 571 226 666 <a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a>
<b>Funding commitment</b>	0.6 Mio. €
<b>Overheads</b>	25% of eligible project costs (excluding subcontracting)
<b>Anticipated number of fundable research partners</b>	1 - 3
<b>Maximum funding per grant awarded to a partner</b>	Maximum 200 000 € per project, regardless of the number of Polish partners in the project consortium.
<b>Eligibility of a partner as a beneficiary institution</b>	<p>Following entities are eligible to apply:</p> <ul style="list-style-type: none"> <li>• Micro, Small, Medium and Large enterprise.</li> <li>• Research organization.</li> <li>• Group of entities (within the meaning of art. 37 section 1, point 1a of The Act of 30 April 2010 on the National Centre for Research and Development, published in Journal of Laws item 1861, 2020;).</li> </ul> <ul style="list-style-type: none"> <li>• Organization must be registered in Poland.</li> <li>• For enterprises it is strongly advised to state in the Pre-proposal application form the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large).</li> <li>• A condition for the participation of a group of entities as the Applicant in the competition is its formal existence on the date of submission of the pre-proposal, confirmed by its members concluding, at least conditionally, agreement on the creation of a group of entities.</li> <li>• Please note that group of entities counts as two project partners from Poland (it meets the limit on the number of participants from the same country, please refer to call text for details).</li> </ul>
<b>Eligibility of costs, types and their caps</b>	<p>The eligible costs shall be the following:</p> <ol style="list-style-type: none"> <li>1. <b>personnel costs</b> (researchers, technicians and other supporting staff to the extent employed on the research project);</li> <li>2. <b>operating costs</b> including costs of instruments, equipment, technical knowledge, patents, costs for buildings and land, costs of materials, supplies and similar products incurred directly as a result of the research activity.</li> </ol>

	<p>3. <b>cost of contractual research</b>, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national expert panel.</p> <p>4. <b>additional overheads</b> incurred indirectly as a result of the research project; that costs are exactly <b>25%</b> of eligible project costs and are counted as a multiplication by percentage given above and the rest of direct costs, excluding subcontracting (<b>3</b>); It means <math>4=(1+2)*25\%</math>.</p>																				
	<p>Funding quota of Polish participants can be up to 100% for universities or research organizations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation, under the Regulation of the Minister of Science and Higher Education of 19 August 2020 on criteria and rules on granting state aid by the National Centre for Research and Development, published in Journal of Laws item 1456, 2020.</p>																				
	<table border="1"> <thead> <tr> <th></th> <th>Large Enterprises</th> <th>Medium Enterprises</th> <th>Small Enterprises</th> <th>Universities and research organizations</th> </tr> </thead> <tbody> <tr> <td><b>Fundamental/Basic Research</b></td> <td>Not eligible</td> <td>Not eligible</td> <td>Not eligible</td> <td>Not eligible</td> </tr> <tr> <td><b>Industrial/Applied Research</b></td> <td>Up to 50+15 (max 65 %)</td> <td>Up to 50+10+15 (max 75 %)</td> <td>Up to 50+20+15 (max 80 %)</td> <td>Up to 100 %</td> </tr> <tr> <td><b>Experimental development</b></td> <td>Up to 25+15 (max 40 %)</td> <td>Up to 25+10+15 (max 50 %)</td> <td>Up to 25+20+15 (max 60 %)</td> <td>Up to 100 %</td> </tr> </tbody> </table>		Large Enterprises	Medium Enterprises	Small Enterprises	Universities and research organizations	<b>Fundamental/Basic Research</b>	Not eligible	Not eligible	Not eligible	Not eligible	<b>Industrial/Applied Research</b>	Up to 50+15 (max 65 %)	Up to 50+10+15 (max 75 %)	Up to 50+20+15 (max 80 %)	Up to 100 %	<b>Experimental development</b>	Up to 25+15 (max 40 %)	Up to 25+10+15 (max 50 %)	Up to 25+20+15 (max 60 %)	Up to 100 %
		Large Enterprises	Medium Enterprises	Small Enterprises	Universities and research organizations																
<b>Fundamental/Basic Research</b>	Not eligible	Not eligible	Not eligible	Not eligible																	
<b>Industrial/Applied Research</b>	Up to 50+15 (max 65 %)	Up to 50+10+15 (max 75 %)	Up to 50+20+15 (max 80 %)	Up to 100 %																	
<b>Experimental development</b>	Up to 25+15 (max 40 %)	Up to 25+10+15 (max 50 %)	Up to 25+20+15 (max 60 %)	Up to 100 %																	
<p>Only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule.</p>																					
<b>Conditions for PAO funding</b>	Funding is only available for project partners, meeting eligibility criteria given above.																				
<b>Submission of the proposal at the national level</b>	Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established. Additionally, Project Consortium Agreement is required for the signature of national agreement.																				
<b>Further guidance</b>	Please refer to call text.																				

## SLOVAKIA, SAS

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Slovakia
<b>Funding organization</b>	Slovak Academy of Sciences (SAS)
<b>National contact person</b>	Silvia Kecerova, PhD. International Cooperation Dpt., SAS Phone: +421257510118 Email: kecerova@up.upsav.sk
<b>Funding commitment</b>	120,000 €
<b>Overheads</b>	Up to 20% of the direct costs
<b>Anticipated number of fundable research partners</b>	1
<b>Maximum funding per grant awarded to a partner</b>	120,000 €
<b>Eligibility of a partner as a beneficiary institution</b>	<p><b>Only research institutes and/or centres of the Slovak Academy of Sciences are eligible organisations for funding by the SAS (up to 100%).</b> The main applicant must have an employment contract with the SAS institute/centre on behalf of which the application is being submitted. If his/her contract is on a part-time basis, it must be for more than 50% of standard working time. All members of the applicant's team except doctoral students must, too, have employment contracts with the same or another SAS institute/centre.</p> <p>Applicants from other Slovak R&amp;D centres (universities and/or other organisations from Slovakia) can join project consortia only as collaborators who must secure their own funding.</p>
<b>Eligibility of costs, types and their caps</b>	Funding available for eligible Slovak researchers is up to 120,000 EUR per project (i.e. 40,000 EUR per year) in accordance with the SAS Presidium's resolution no. 136 (of 14 October 2021), of which 45,000 EUR is an in-kind contribution (spoluúčasť) of the respective SAS institute or centre in the form of permanent salaries. This must be declared in a Letter of Commitment sent to the national contact point by the application deadline. A template will be published alongside the Call announcement at <a href="http://www.sav.sk">www.sav.sk</a> in the 'International Cooperation' section (Medzinárodná spolupráca).

	<p>Costs other than the in-kind contribution (Personnel costs, Consumables, Travel costs, Equipment, Other direct costs, Overheads) up to 75,000 EUR must comply with specific rules and limits outlined in the financial rules for awarding SAS grants for international research projects available at:</p> <p><a href="https://www.sav.sk/?lang=sk&amp;doc=services-news&amp;source_no=25&amp;news_no=7569">https://www.sav.sk/?lang=sk&amp;doc=services-news&amp;source_no=25&amp;news_no=7569</a></p> <p><b>Applicants are strongly encouraged to read the said document carefully and to contact the national contact point before submission in order to ensure compliance.</b></p>
<b>Conditions for PAO funding</b>	<p>The SAS does not fund PAOs/patient representatives.</p>
<b>Submission of the proposal at the national level</b>	<p>Submission of an application at the national level will be required once the international evaluation and the ranking list have been performed and endorsed by the Call Steering Committee. Only the Slovak partners of the projects recommended for funding will be invited to submit the national-level application. The final decision on funding of the Slovak partners must be approved by the SAS Presidium.</p>
<b>Further guidance</b>	<ul style="list-style-type: none"> <li>• <a href="http://www.sav.sk">www.sav.sk</a></li> <li>• 133 Act of February 19, 2002, on the Slovak Academy of Sciences</li> <li>• <a href="#">Financial rules for awarding SAS grants for international research projects</a></li> </ul>

## SPAIN, ISCIII

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Spain
<b>Funding Organisation</b>	National Institute of Health Carlos III - Instituto de Salud Carlos III (ISCIII) <a href="http://www.isciii.es">www.isciii.es</a>
<b>National Funding Programme</b>	Acción Estratégica en Salud (AES 2023)
<b>National Contact Point for the 10th call of E-RARE</b>	Mauricio Garcia-Franco Email: <a href="mailto:mauriciog@isciii.es">mauriciog@isciii.es</a> Tel: (+34) 91 822 28 85
<b>Initial funding pre-commitment</b>	1 M€ (pending of approval of Spanish State Budget) 4-6 groups tentatively envisaged to be funded.
<b>Maximum funding per awarded Spanish project partner</b>	<p><b>Maximum funding from ISCIII per awarded Spanish project partner r</b></p> <ul style="list-style-type: none"> <li>• Up to 180,000 € per partner (overheads included)</li> <li>• Up to 260,000 € per coordinator (overheads included)</li> </ul> <p>Overheads according to AES 2023: 25%</p> <p><b>Projects' duration:</b> from 24 months to 36 months.</p> <p>The level of funding will take into account the evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, the participation of the primary health care and the financial resources available.</p>
<b>Eligible institutions</b>	<p><b>Eligible institutions</b></p> <ul style="list-style-type: none"> <li>• <b>Hospitals, primary health care or public health administration of the Spanish National Health System (SNS)</b> These institutions may manage research via a foundation regulated in accordance with the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted).</li> <li>• <b>Accredited Health Research Institutes</b> (Institutos de Investigación Sanitaria acreditados, IIS) Accredited according to the RD 279/2016 (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in <a href="#">this link</a>.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>CIBER.</b> Team members, applying to the call, must be from at least two groups belonging to CIBER in two different home institutions, and one of these two should be a Hospital, primary health care or public health administration of the Spanish National Health System (SNS) or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS). Please contact Cristina Rodríguez (<a href="mailto:cristina.rodriguez@ciberisciii.es">cristina.rodriguez@ciberisciii.es</a>) for more information related to CIBER's eligibility.</li> <li>• <b>Applicants from ISCIII</b> are eligible. Eligibility criteria from AESI 2023 apply.</li> <li>• <b>Private health entities and institutions, Public Research Institutions (OPIs)</b> as defined in article 47 of Law 14/2011, of 1 June, in accordance with the provisions of Royal Decree 202/2021, of 30 March, <b>public Universities and private Universities with proven R&amp;D activity capacity, other public R&amp;D centres.</b> These entities can <b>only</b> participate if they apply together with Hospitals, primary health care or public health settings of the Spanish National Health System (SNS), or Accredited Health Research Institutes (Institutos de Investigación Sanitaria acreditados, IIS) in the same proposal. It is not allowed to apply independently, thus <b>there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.</b></li> </ul> <p><b>PLEASE NOTE:</b></p> <ul style="list-style-type: none"> <li>• Please be aware that in AES2023 some Institutions may be declared as ineligible to receive funds by ISCIII in this call. Spanish Applicants should check in the web page of ISCIII for this.</li> <li>• Same beneficiary institution cannot participate with more than one partner in the same project proposal.</li> </ul>
<p><b>Eligibility of PI and team members</b></p>	<ul style="list-style-type: none"> <li>• Principal Investigators (PI) can only participate in one project proposal per call.</li> <li>• Principal Investigators (PIs) belonging to an <b>Accredited Health Research Institutes (IIS)</b> could apply <b>only from the IIS.</b></li> <li>• The Principal Investigator (PI) and all members of the research group must belong to the eligible institutions in the call.</li> <li>• Only one PI per beneficiary institution may be funded within the same proposal.</li> <li>• PIs that have an ongoing International Collaboration (PCIN) project of the same initiative and purpose that this call and that the project has an ending date after the 31<sup>st</sup> of December 2023 will not be able to apply for this call. This incompatibility will affect only to the PI. And this incompatibility will not apply in the case that the PI participate as coordinator in the new application or in the ongoing project.</li> <li>• For additional incompatibilities please check AES2023.</li> </ul>

	<p><b>Excluded</b> personnel as Principal Investigator (PI):</p> <ul style="list-style-type: none"> <li>• Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR)</li> <li>• Those undergoing research training (e.g. PhD students, or “Río Hortega” contracts).</li> <li>• Those undergoing postdoctoral training (e.g. “Sara Borrell” or “Juan de la Cierva” contracts).</li> <li>• Researchers contracted by a RICORs and platforms funded by ISCIII.</li> </ul>
<p><b>Eligible costs, types and their caps</b></p>	<ul style="list-style-type: none"> <li>• <b>Personnel costs:</b> <ul style="list-style-type: none"> <li>- It will be eligible personnel costs for contracts with the needed professional category (superior technician, BSc (grado), MSc (máster), PhD (doctor) for the project development accordingly to the published salary tables in AES2023 / ISCIII's webpage.</li> <li>- Contracts for PhD students will be done in the framework of National Subprogramme for Training (scholarships are not eligible).</li> <li>- Personnel costs will be eligible with a maximum of 36 PM in total for the personnel contracts altogether.</li> <li>- The hiring of permanent personnel already belonging to the beneficiary entity or members of the research team will not be considered eligible expenses.</li> <li>- Duration of the contracts: during the whole or part of the duration of the project.</li> </ul> </li> <li>• <b>Other eligible costs:</b> Current costs, small scientific equipment, disposable materials, travelling expenses, complementary expenses (use of central and general research support services of the beneficiary entity), publication and dissemination of results and other costs as included in AES 2023 that can be justified as necessary to carry out the proposed activities. <ul style="list-style-type: none"> <li>• <b>Overheads</b>, according to AES 2023 (25%)</li> </ul> </li> <li>• <b>Double funding of the same concept is not allowed</b></li> </ul>
<p><b>Conditions for PAO funding</b></p>	<p>The ISCIII does not fund PAOs/patient representatives.</p>
<p><b>Submission of the proposal at the national level</b></p>	<ul style="list-style-type: none"> <li>• National applications <b>will be required by ISCIII</b>.</li> </ul> <p>Due to administrative and legal regulations, the Institute of Health Carlos III establishes the <b>31st of October 2023</b> as the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII, which must present their National application in the period stated in AES 2023 (1-15</p>

	November 2023). Any concerned applicant in a proposal for which no final decision has been made by the deadline of 31.10.2023, could be declared not fundable by ISCIII.
<b>Submission of other information at the national level</b>	As specified by AES 2023.
<b>Submission of financial and scientific reports at the national level</b>	As specified by ISCIII's instructions (please check ISCIII's webpage).
<b>Requirements on data and repositories</b>	<ul style="list-style-type: none"> <li>• Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, and data instruments survey tools. Regarding genomic data it is understood association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the <a href="#">"ELIXIR Core Data Resources"</a> or if non-European repositories or data bases they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).</li> <li>• ISCIII may no fund a project that requires the construction of new repositories and/or a data base without decommissioning plans or ensured sustainability after the project's end of funding.</li> </ul>
<b>Requirements for clinical studies</b>	Spanish groups that participate in a proposal performing a clinical study, <b>must include</b> in their team a member from their scientific node of the EU Clinical Trials Network (SCReN or ECRIN-ERIC) or if it does not apply, a member from the personnel of their Clinical Research Supporting Platform of their institutions (UIC). In the proposals that performs a clinical study, it must be specified in the proposal who is exactly the mandatory member of these dedicated Units.
<b>Acknowledgements</b>	Any publication, data base, product or event protected with IPR or not, resulting from the granted projects must acknowledge "Award no. XX by ISCIII through AES 2023 and within the European Joint Programme Rare Diseases framework", even after the end of the project, including other specific acknowledgments that could be requested by ISCIII to the granted project. For more information, please see ISCIII's ROR <a href="#">here</a> .



**SWEDEN, SRC**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Sweden
<b>Funding organization</b>	Swedish research council, SRC <a href="http://www.vr.se">www.vr.se</a>
<b>National contact person</b>	Louise Rügheimer E-mail: <a href="mailto:Louise.rugheimer@vr.se">Louise.rugheimer@vr.se</a> Phone: +46(0)8 122 13 618
<b>Funding commitment</b>	20 MSEK, approximately 1 820 000€
<b>Overheads</b>	The grant amount includes indirect costs.
<b>Anticipated number of fundable research partners</b>	2-4
<b>Maximum funding per grant awarded to a partner</b>	For Swedish participation in a consortium, the maximum amount that may be applied for is 4 500 000 SEK (approximately 450 000 EUR) for a consortium with 1 Swedish partner, or 6 000 000 SEK (approx. 600 000 EUR) if the consortia contain two Swedish partners. Use the exchange rate of 1 EURO=10,13 SEK to calculate actual grant amounts for the application
<b>Eligibility of a partner as a beneficiary institution</b>	Not applicable
<b>Eligibility of costs, types and their caps</b>	The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person's activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs. Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.
<b>Conditions for PAO funding</b>	

<p><b>Submission of the proposal at the national level</b></p>	<p>All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application using the Swedish Research Council's application system Prisma. The application form in Prisma can be reached from the call text at the SRC website: <a href="#">Swedish</a> and <a href="#">English</a></p> <p><b>Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the Prisma call will result in the Swedish partner being declared ineligible.</b></p> <p>All Swedish applicants must communicate with the EJP RD national contact person regarding their intention to participate in the call, before submission of the consortium application.</p>
<p><b>Further guidance</b></p>	<p>See national call texts for all national requirements: <a href="#">Swedish</a> and <a href="#">English</a></p>

SWEDEN, VINNOVA

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

Country	Sweden
Funding organization	Vinnova <a href="http://www.vinnova.se">www.vinnova.se</a>
National contact person,	Gunnar Sandberg, <a href="mailto:gunnar.sandberg@vinnova.se">gunnar.sandberg@vinnova.se</a> +46 8 4546445
Funding commitment	9MSEK, 900 000 Euro.
Overheads	
Anticipated number of fundable research partners	3-5
Maximum funding per grant awarded to a partner	The maximum amount of funding for Swedish participation is 3 million SEK for 1 Swedish partner and 4.5 million SEK for 2 Swedish partners. <b>The consortia need to include at least one Swedish partner from industry when applying for funding from Vinnova.</b>
Eligibility of a partner as a beneficiary institution	<b>The Swedish participation applying for funding from Vinnova should have at least one partner from industry.</b> Universities, public research institutes, healthcare providers and industry. For more information see <a href="http://Vinnova.se">Vinnova.se</a>
Eligibility of costs, types and their caps	Universities, public research institutes and public healthcare providers may receive funding of up to 100 % of their eligible costs, provided that the project is part of their non-economic activities. Large companies can apply for 20 % of their eligible costs. Small and medium sized companies can apply for 70 % of their eligible costs The eligible cost are defined in: <a href="#">Terms and conditions for Vinnova funding   Vinnova</a>
Conditions for PAO funding	Approved administrating organisations see <a href="http://Vinnova.se">Vinnova.se</a>

<p><b>Submission of the proposal at the national level</b></p>	<p>General condition for grant application (<a href="#">Find the right funding   Vinnova</a>) Swedish applicants must also apply via the Vinnova web portal (<a href="#">Find the right funding   Vinnova</a>), where the Swedish project partner/s should add the requested information and upload the EJP-RD JTC 2022 project plan. Please follow the instructions on the national call page. If you have any questions don't hesitate to email or call one of the Vinnova contact persons.</p>
<p><b>Further guidance</b></p>	<p>General condition for grant application (<a href="#">Find the right funding   Vinnova</a>)</p>

**SWITZERLAND, SNSF**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Switzerland
<b>Funding organisation</b>	Swiss National Science Foundation ( <a href="#">SNSF</a> )
<b>National contact person</b>	Dr Tobias Braun Division Biology and Medicine Wildhainweg 3, P.O. Box, CH-3001 Bern Phone: +41 31 308 21 67 <a href="mailto:tobias.braun@snf.ch">tobias.braun@snf.ch</a>
<b>Funding commitment</b>	1 Mio Swiss Francs (equivalent to approx. 0.9 Mio €)
<b>Overheads</b>	Overhead costs may not be included in the Swiss project budget. Overhead contributions, calculated on the basis of the total research funding given to a particular institution through all SNSF funding instruments, are paid directly to the applicant's institution on a yearly basis.
<b>Anticipated number of fundable research partners</b>	3-4, each Swiss applicant may be partner in only one EJP RD JTC 2023 proposal (Art.7.3, <a href="#">SNSF Regulations on Project Funding</a> ).
<b>Eligibility of a partner as a beneficiary institution</b>	n.a.
<b>Eligibility of principal investigator or other research team member</b>	<p>Where not otherwise specified, the <a href="#">SNSF Funding Regulations</a>, in particular, the <a href="#">SNSF Regulations on Project Funding</a> apply:</p> <ul style="list-style-type: none"> <li>• <a href="#">SNSF Funding Regulations</a></li> <li>• <a href="#">General Implementation Regulations for the Funding Regulations</a></li> <li>• <a href="#">SNSF Regulations on Project Funding</a></li> </ul> <p>All Swiss partners in EJP RD projects must meet the eligible criteria for applicants in <a href="#">SNSF Project Funding</a>. Swiss partners who have not previously obtained a project grant from division Biology and Medicine must contact the national contact point to confirm their eligibility as an applicant prior to submitting a proposal to the EJP RD JTC 2023.</p> <p>Foreign members of the international consortia applying for funding through the EJP RD JTC 2023 cannot be declared as "project partners" in the sense of Art. 11.2 of the <a href="#">SNSF Funding Regulations</a> and may not receive any funding through the Swiss partner.</p>

	<p>Article 17 of the <a href="#">SNSF Funding Regulations</a> applies, i.e. EJP RD proposals with overlapping funding periods with ongoing SNSF grants are only allowed if the two research projects are thematically distinct and pursue different goals.</p> <p>Grants given to Swiss partners will be managed according to <a href="#">SNSF Funding Regulations</a>.</p>
	<p>Please note: The SNSF exclusively funds research conducted for non-commercial purposes. Pursuant to the Swiss Research and Innovation Promotion Act (RIPA) and the legal framework of the SNSF, no research grants are awarded if the relevant research is conducted for directly commercial purposes or if the persons involved in the research work do not enjoy full academic freedom.</p>
<b>Eligibility of costs, types and their caps</b>	<p>According to the <a href="#">SNSF Regulations on Project Funding</a> (article 8), the following costs may be covered:</p> <ul style="list-style-type: none"> <li>- the salaries of scientific and technical staff in research projects within the scope of the salary ranges and rates prescribed by the SNSF;</li> <li>- material costs that are directly related to the research work, namely material of enduring value, expendable items, field expenses, travel expenses, third-party charges, cost of computing time and data as well as of providing open access to research data;</li> <li>- direct costs incurred through the use of research infrastructure linked to the research work;</li> <li>- costs for the organisation of conferences and workshops in connection with the funded research;</li> <li>- costs for national and international cooperation and networking activities carried out in connection with the funded research.</li> </ul>
<b>Conditions for PAO funding</b>	<p>According to our eligibility criteria, PAO are <u>not</u> eligible as partners.</p>
<b>Submission of the proposal at the national level</b>	<p>Swiss partners are required to submit the pre-proposal and the full proposal to <a href="http://www.mySNF.ch">www.mySNF.ch</a> together with the submission of the respective proposals to the EJP RD Joint Call Secretariat. For this, Swiss partners need a personal account on <a href="http://www.mySNF.ch">www.mySNF.ch</a>. The SNSF office may ask Swiss partners to submit supplemental information as needed.</p>
<b>Submission of financial and scientific reports at the national level</b>	<p>Yearly financial reports for the use of SNSF funds and a scientific report at the end of the project.</p>
<b>Further guidance</b>	<p>If funded, consortia including Swiss partners must submit a data management plan (DMP) which complies with the <a href="#">SNSF policy on open research data</a>.</p>

**TÜRKIYE, TUBITAK**

It is strongly advised that all applicants contact their EJP RD National/Regional Contact Point in good time before the submission of a proposal

<b>Country</b>	Türkiye
<b>Funding organization</b>	The Scientific and Technological Research Council of Turkey, <a href="https://tubitak.gov.tr/">https://tubitak.gov.tr/</a>
<b>National contact person</b>	Dr. Emine DEREBAY YILDIZ Phone: +90 312 298 1195 E-mail: <a href="mailto:emine.derebay@tubitak.gov.tr">emine.derebay@tubitak.gov.tr</a> <b>Applicants are strongly recommended to reach the national contact point during the all application process.</b>
<b>Funding commitment</b>	0,5 M Euro
<b>Overheads</b>	Overheads are eligible costs only for academy and public institutions and subjected to the terms and conditions stated in TUBITAK 1071 Programme.
<b>Anticipated number of fundable research partners</b>	3-4 projects
<b>Maximum funding per grant awarded to a partner</b>	Maximum funding cannot exceed <b>2.500.000 TL</b> for each project (regardless of the number of the partners).  For each partner: The maximum funding cannot exceed <b>1.500.000 TL</b> for Universities (public and private), research institutes, and public institutions.  The maximum funding cannot exceed <b>2.500.000 TL</b> for private corporations.  These amounts exclude payments to the PI, Co-PIs and overhead costs.

	<p><u>Percentage of Funding:</u></p> <p><b>Universities (public and private), research institutes and public institutions:</b> 100% of budget of the project will be funded by TUBITAK.</p> <p><b>Large-size Enterprises:</b> 60% of budget of the project will be funded by TUBITAK.</p> <p><b>Small and Medium-size Enterprises:</b> 75% of budget of the project will be funded by TUBITAK.</p> <p>If there is more than one Turkish partner in a single transnational project, these partners should submit joint national application under TUBITAK 1071 Programme (Support Programme for Increasing Capacity to Benefit from International Research Funds and Participation in International R&amp;D Cooperation) via project application system of TUBITAK.</p> <p><b>For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.</b></p>
<p><b>Eligibility of project duration</b></p>	<p>Maximum 3 years (36 month)</p>
<p><b>Eligibility of a partner as a beneficiary institution</b></p>	<p>Legal body: Universities (public and private), research institutes, public institutions and organizations, training and research hospitals. Large-size enterprises and SMEs.</p> <p><b>For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.</b></p>
<p><b>Eligibility of costs, types and their caps</b></p>	<p>Eligible types of funding under this programme are limited to personnel costs, travel and subsistence, equipment, consumables and subcontracting/services. Projects intended to build infrastructure cannot be supported.</p> <p><b>For further information, applicants should follow the announcements regarding this call under the official website of TUBITAK.</b></p>
<p><b>Conditions for PAO funding</b></p>	<p>PAOs are not eligible for funding. However, the project coordinator can make a payment to a PAO only if the PAO is able to bill the provided service.</p>

<p><b>Submission of the proposal at the national level</b></p>	<p>Yes</p> <p>Applicants from Turkey must make a national application through TUBITAK application system: <a href="http://uidb-pbs.tubitak.gov.tr/">http://uidb-pbs.tubitak.gov.tr/</a>.</p> <p><b>Applicants are strongly recommended to reach the national contact point during the all application process.</b></p>
<p><b>Submission of other information at the national level</b></p>	<p>Yes, for proposals selected for funding.</p> <p>Turkish partners in the projects selected for funding are obliged to provide Ethics Approval Certificate and/or Legal Permission Licences and other related documents (if necessary).</p>
<p><b>Submission of financial and scientific reports at the national level</b></p>	<p>Yes, according to national regulations.</p>
<p><b>Further guidance</b></p>	<p>Please check the <a href="#">guide</a> for national application rules.</p>